Close Menu

NEW YORK (GenomeWeb News) – Drug firm Summit and the Children's National Medical Center in Washington today announced a collaboration for the development of a proteomic assay to measure biomarkers in support of Summit's candidate drug for Duchenne Muscular Dystrophy (DMD).

Under the terms of the deal, Yetrib Hathout, a principal investigator at CNMC's Center for Genetic Medicine Research, will develop a mass spectrometry-based assay to measure levels of a protein called utrophin in DMD muscle that may prove useful in treating the disease.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Rady Children's Institute for Genomic Medicine and Deloitte are looking into the use of drones to transport samples for testing. 

Direct-to-consumer genetic testing firm 23andMe is laying off about 100 people.

Researchers from Northwestern University examined dust for antibiotic-resistance genes, New Scientist reports. 

In Science this week: researchers present a computational method for predicting cellular differentiation state from single-cell RNA sequencing data, and more.